Skip to main content

Table 5 ICERs of scenario analyses from the Chinese private payer perspective (CNY per QALY gained)

From: Methodology and results of cost-effectiveness of LDL-C lowering with evolocumab in patients with acute myocardial infarction in China

 

PEACE

BERSON

SuValue®

LDL-C ≥ 100 mg/dl

SuValue®

LDL-C ≥ 70 mg/dl

Evo 140mgQ2W

Evo 420mgQM

Evo 140mgQ2W

Evo 420mgQM

Evo 140mgQ2W

Evo 420mgQM

Evo 140mgQ2W

Evo 420mgQM

Time horizon

        

5 years

538578.65

840636.79

481061.72

873164.78

174043.04

360901.94

301236.99

535743.77

10 years

264847.73

420839.28

225087.72

422267.59

75562.59

175411.94

142255.13

266727.23

15 years

173410.07

278957.63

139891.58

268955.17

45586.22

114800.18

91036.01

176928.74

20 years

135696.37

220129.52

101220.39

198558.46

33040.08

88467.34

68849.69

137449.49

30 years

118511.82

194227.70

75503.67

152378.28

24439.97

71303.95

53946.33

111850.08

35 years

117217.93

192854.18

72506.95

147936.29

NA

NA

NA

NA

Starting age

        

65-year

108771.20

177305.36

64624.43

129223.90

NA

NA

NA

NA

70-year

93050.81

152702.01

49543.94

101051.16

26725.74

74512.59

56998.67

116023.46

75-year

76221.16

127484.02

36443.19

77920.22

20824.50

58466.14

43803.33

90095.23

Discount rate

        

3%

108174.04

177445.07

72565.94

146128.62

23150.27

67577.18

51123.46

105957.15

6%

129263.01

210373.48

88758.57

176048.14

29692.79

81585.10

62878.15

127051.85

Annual Cost of Stains (CNY)a

        

118.86

120022.58

197045.16

81914.54

164396.45

25227.33

74536.00

56608.02

117548.43

5470.28

123863.78

200886.36

83735.51

166224.98

29521.56

78830.23

60907.22

121847.64

Costs of CV-related deathb

        

Death due to stroke 1

100522.74

177545.32

61045.06

143405.39

2979.10

52287.76

34099.45

95039.86

Death due to stroke 2

114482.41

191504.99

75468.74

157909.73

18935.65

68244.32

50234.53

111174.94

Death due to MI 1

94656.25

171678.83

55830.30

137955.69

Dominance

41690.59

24793.53

85733.94

Death due to MI 2

69467.93

146490.51

24696.42

106532.67

Dominance

4528.46

Dominance

49006.85

Utilityb

        

Higher utility

130475.81

218258.57

90208.50

180284.52

30171.23

84421.29

64950.45

132258.00

Lower utility

105182.33

175947.90

78362.40

155803.00

25665.76

71814.68

54882.83

111757.38

UK- utility

119895.54

200560.01

88272.39

174919.55

28466.22

79650.55

60874.92

123959.02

Hospital classificationc

        

County hospitals

139220.80

216243.38

102079.64

184879.97

54709.26

104017.93

85032.51

145972.92

County-level municipal hospitals

134508.03

211530.61

96579.00

179335.09

46786.37

96095.03

77442.66

138383.07

Prefecture-level municipal hospitals

120332.05

197354.62

81196.28

163645.82

24721.08

74029.74

56226.15

117166.56

Provincial hospitals

118859.87

195882.45

78581.27

160974.85

20756.61

70065.28

52612.97

113553.38

Hospitals directly under the Health Commission

113799.45

190822.02

73017.46

155300.28

12840.81

62149.47

44959.21

105899.62

  1. CNY, Chinese Yuan; Dominance, ICERs, incremental cost-effectiveness ratio; Lower cost, higher utility; LDL-C, low-density lipoprotein cholesterol; MI, myocardial infarction; NA, not applicable
  2. italic text: ICERs below CNY 85698 (US$12741); bold text: ICERs above CNY 257094 (US$38224).
  3. a: the maximum and minimum annual cost of statins, more detailed parameters are shown in Supplementary Tables S4
  4. b: CV-related mortality costs used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S5
  5. c: Utility used in other CEA studies and beyond the scope of sensitivity analysis, more detailed parameters are shown in Supplementary Tables S6
Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us